Voyager Therapeutics, Inc. financial data

Symbol
VYGR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
75 Hayden Avenue, Lexington, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 521 % +89.5%
Debt-to-equity 50.3 % -53.7%
Return On Equity -1.28 % -101%
Return On Assets -0.85 % -102%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.4M shares +25.6%
Common Stock, Shares, Outstanding 54.3M shares +25.1%
Entity Public Float 489M USD +330%
Common Stock, Value, Issued 54K USD +25.6%
Weighted Average Number of Shares Outstanding, Basic 57.1M shares +40.6%
Weighted Average Number of Shares Outstanding, Diluted 57.1M shares +35.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 19.5M USD -89.8%
Research and Development Expense 101M USD +55%
General and Administrative Expense 35.4M USD +9.44%
Operating Income (Loss) -17.1M USD -118%
Nonoperating Income (Expense) 14.7M USD +135%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.33M USD -102%
Income Tax Expense (Benefit) 718K USD -98%
Net Income (Loss) Attributable to Parent -3.04M USD -103%
Earnings Per Share, Basic -0.17 USD/shares -107%
Earnings Per Share, Diluted -0.17 USD/shares -107%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 143M USD -46.7%
Marketable Securities, Current 256M USD +5037%
Cash, Cash Equivalents, and Short-term Investments 401M USD +46.5%
Other Assets, Current 2.63M USD -37.9%
Assets, Current 409M USD +35.2%
Property, Plant and Equipment, Net 17.4M USD +1.42%
Operating Lease, Right-of-Use Asset 39.2M USD +161%
Assets 470M USD +39.6%
Accounts Payable, Current 7.58M USD +105%
Employee-related Liabilities, Current 2.25M USD -9.72%
Accrued Liabilities, Current 7.6M USD -0.58%
Contract with Customer, Liability, Current 51.4M USD +806%
Liabilities, Current 72.6M USD +264%
Contract with Customer, Liability, Noncurrent 13.2M USD -83.3%
Operating Lease, Liability, Noncurrent 42M USD +115%
Other Liabilities, Noncurrent 43M USD +110%
Liabilities 129M USD +7.85%
Accumulated Other Comprehensive Income (Loss), Net of Tax -506K USD -283%
Retained Earnings (Accumulated Deficit) -273M USD -1.13%
Stockholders' Equity Attributable to Parent 341M USD +57.1%
Liabilities and Equity 470M USD +39.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 58.8M USD -52.4%
Net Cash Provided by (Used in) Financing Activities 113M USD +260%
Net Cash Provided by (Used in) Investing Activities -96.1M USD -763%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 54.3M shares +25.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 75.6M USD -55.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 146M USD -45.9%
Deferred Tax Assets, Valuation Allowance 82.6M USD -29.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 89M USD -28.7%
Depreciation 1.2M USD +11.3%
Payments to Acquire Property, Plant, and Equipment 2.14M USD +321%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -3.42M USD -103%
Property, Plant and Equipment, Gross 31.5M USD -10.1%
Operating Lease, Liability, Current 5.94M USD +103%
Deferred Tax Assets, Operating Loss Carryforwards 13.7M USD -71%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 614M USD +26.2%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 160K USD +900%
Current Federal Tax Expense (Benefit) 1.25M USD
Deferred Tax Assets, Net of Valuation Allowance 6.43M USD -13.4%
Share-based Payment Arrangement, Expense 12.2M USD +27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%